About this role
Glioblastoma multiforme (GBM) is among the most lethal human cancers. The standard treatment—surgery followed by radiotherapy (RT) and temozolomide (TMZ) provides a median survival of around 14 months and is often accompanied by severe toxicity. Recurrence occurs in 90% of patients within 2 years, while re-irradiation and alternative treatments are constrained by high morbidity. Novel therapeutic approaches that address the main challenges in GBM treatments are urgently needed and include I) radioresistance, II) infiltration, and III) immunosuppression.
The main objective of InnovaRTBRAIN – Innovative Radiation Therapy for Brain Tumors – is to tackle those challenges by means of innovative radiotherapy and employing a holistic approach.In this context, thanks to a network of 23 partners InnovaRTBRAIN aims to train 14 doctoral researchers to enhance the efficacy of innovative radiotherapy through combination with immunotherapies. Research and transferable training of the doctoral researchers will be performed in a highly interdisciplinary, intersectoral, and international environment. In addition to acquiring skills related to the research project, they will be trained also in open science, communication and dissemination, responsible research and innovation, circular economy, ethics, data management, entrepreneurship, marketing, intellectual property, and gender dimension in research.
The recruiting organisation Oslo University Hospital (OUH) is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo. The hospital also has nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence. OUH carries out advanced patient treatment, research and clinical trial treatments, and give advice and provide education on international levels. The hospital is Scandinavia’s largest and annually performs more than 1.2 million patient treatments.
The Department of Oncology is located at one site, The Norwegian Radiumhospital. The department carries out intensive research on new cancer treatment methods.
The PHD position is available in the Translational Research Unit, at the Section for Cellular Therapy. The section has a clinical unit producing cell therapy products for patient treatment and a Translational Research Unit developing new types of CAR- and TCR-based treatment for solid cancers.
Oslo University Hospital is a workplace with great diversity. We believe this is essential to perform the tasks required. We pursue diversity among our job applicants and encourage everyone to apply regardless of who you are and what background you have.